2 assets in Gallbladder Melanoma

Therapeutic assets addressing Gallbladder Melanoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cabozantinib Gallbladder Melanoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Gallbladder Melanoma	National Cancer Institute (NCI)	P2	CCC (53)